Comparison efficacy of tow serum therapy methods (serum with bicarbonate and without bicarbonate with soduim) in some factors (cratinin, pH of urine, term negative UA in terms of hemoglobin and granular casts) patients with hemolysis caused by glucose 6-phosphate dehydrogenase enzyme deficiency in Taleghani hospital, Gorgan

considering effect of serum with bicarbonate and serum without bicarbonate with soduim in treatment of hemolysis caused by glucose 6-phosphate dehydrogenase deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013031012765N1

Enrollment

Registered

2013-04-21

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemolysis due to glucose 6-phasphate deficiency. Anaemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency

Interventions

Intervention 1: treatment by serum with bicarbonate, 1.5 times of Maintaining serum volume of dextrose water 5% and for 100 mililiter, 3 meq/lit of bicarbonate. Intervention 2: treatment by serum with

Treatment - Drugs

treatment by serum with bicarbonate, 1.5 times of Maintaining serum volume of dextrose water 5% and for 100 mililiter, 3 meq/lit of bicarbonate

treatment by serum with bicarbonate, 1.5 times of Maintaining serum volume of dextrose water 5% and for 100 mililiter, 3 meq/lit of NaCl.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria is just diagnosis favism. Beans consumption and Highlighted in urine are the first items for diagnosis of favism and it is confirmed by urinalysis that is Hemoglobinuria positive. Exclusion criteria is dissatisfaction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hemoglpbine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: g/dl- according to tests.;Cereatinine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: mg/dl- according to tests.;PH of urine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: by pH meter.;UA-cast. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: BY Urinanalysis.	—

Measure

Time frame

Hemoglpbine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: g/dl- according to tests.;Cereatinine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: mg/dl- according to tests.;PH of urine. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: by pH meter.;UA-cast. Timepoint: befor intevention and after intervention, befor discharge. Method of measurement: BY Urinanalysis.

—

Secondary

Measure	Time frame
Time of admission until discharge. Timepoint: at discharge. Method of measurement: Measuring the time from the moment of admission to hospital discharge.;Number of blood transfusion. Timepoint: during treatment. Method of measurement: The frequency of blood transfusion.;Blood volume injected for each time. Timepoint: during intervention. Method of measurement: ml- Based on the amount of blood recieved at every turn.;Time to clear urine. Timepoint: at the end of intervention. Method of measurement: being negative urine from hemoglobinuria.;Side effects of ficarbonate. Timepoint: after intervention. Method of measurement: basis on observed side effects.	—

Measure

Time frame

Time of admission until discharge. Timepoint: at discharge. Method of measurement: Measuring the time from the moment of admission to hospital discharge.;Number of blood transfusion. Timepoint: during treatment. Method of measurement: The frequency of blood transfusion.;Blood volume injected for each time. Timepoint: during intervention. Method of measurement: ml- Based on the amount of blood recieved at every turn.;Time to clear urine. Timepoint: at the end of intervention. Method of measurement: being negative urine from hemoglobinuria.;Side effects of ficarbonate. Timepoint: after intervention. Method of measurement: basis on observed side effects.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges beigom Mirbehbahani, Skineh Mohammadian

Hematology & Oncology Research Center, Golestan University of Medical Sciences

n.mirbehbahani@gmai.com, saminmohammadian@gami.com+98 17 1232 8539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026